A Novartis subsidiary is partnering with a Canadian cannabis company to sell medical marijuana worldwide.

Offspring of rats exposed to vaporized cannabis had difficulty switching strategies to get a sugar reward, according to a study presented at the Society for Neuroscience conference.

The country is the second in Africa to permit cannabis cultivation, but months after approval there’s been little uptake by farmers and no scientific proposals.

Epidiolex, a cannabis-derived medicine for epilepsy, will prompt federal regulatory changes that could crack open access to study the plant.

NIDA pharmacologist Michael Baumann explains how “unscrupulous vendors” hijacked compounds used in neuroscience and turned them into dangerous drugs.

Patients will be able to access the drug with a prescription, and there are no plans to allow for recreational use.

The coming legalization of recreational marijuana is already increasing funding for studies, but regulations on such research have been slow to change.

As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.

Marijuana ointments as cancer treatments remain a distant prospect.